Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A2 mass in type 2 diabetes mellitus: Relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity

Publication | Closed Access

DOI

Citations

References

2012

Year

Alexander Constantinides, Rindert de Vries, J.J.J. van Leeuwen, Thomas Gautier, L. Joost van Pelt, Alexandros D. Tselepis, Laurent Lagrost, Robin P.F. Dullaart

European Journal of Internal Medicine

InflammationMetabolic SyndromeBiochemistryCardiovascular DiseaseBezafibrate DecreasesMedicineDiabetesPhysiologyType 2HyperlipidemiaLipoprotein MetabolismDiabetes MellitusPharmacologyAtherosclerosisDyslipidemiaHealth Sciences